7 Articles in March 2026
Why Did Peptide Sciences Shut Down? Timeline, FDA Pressure, and What It Means for the Industry
Peptide Sciences, the largest gray-market research peptide vendor in the U.S., voluntarily shut down on March 6, 2026. A breakdown of the FDA enforcement actions, pharmaceutical lawsuits, and new legislation that led to the closure.
FDA Peptide Category 1 vs Category 2: Complete List and What It Means for Access
Understanding the FDA's Category 1 and Category 2 bulk drug substance classifications for peptides, which compounds fall into each group, and how 2026 reclassification proposals could reshape compounding pharmacy access.
Are Peptides Legal for Veterinary Use? FDA, DEA, and State Regulations
A detailed look at the legal framework governing peptide use in animals, including FDA animal drug rules, extra-label use under AMDUCA, DEA scheduling considerations, and state veterinary board regulations.
Peptide Patent Wars: Novo Nordisk, Eli Lilly, and the Fight Over GLP-1 Compounding
An analysis of the ongoing legal battles between pharmaceutical giants Novo Nordisk and Eli Lilly and the compounding pharmacy industry over GLP-1 receptor agonist patents, FDA shortage declarations, and patient access.
FTC Crackdown on Peptide Advertising: Social Media, Influencer Marketing, and Compliance
How the FTC is targeting peptide advertising on social media and through influencers, and what companies need to do to stay compliant.
Australia Peptide Laws: TGA Regulations, Import Rules, and Scheduling
An analysis of Australian peptide laws covering TGA scheduling, import restrictions, and how the regulatory framework compares to the US and UK.
Are Peptides Legal in Illinois? 2026 Laws, Compounding Rules, and Telehealth
A breakdown of Illinois peptide laws in 2026, including compounding pharmacy rules, IDFPR oversight, and telehealth prescribing regulations.